Acting as a voice for the life sciences and biotech industry, BIA connects businesses to help them grow and deliver world-changing innovation. Working with BIA will amplify TauRx’s position within the wider life sciences sector, making vital connections to advance its research in tau pathology in neurodegenerative diseases.
Head of Commercial and Communications, Rebecca Andersen, said: “With someone developing dementia every three seconds, it is essential that we continue to focus on finding a safe and effective treatment for Alzheimer’s disease, the cause of over 50% of dementia cases.
“Of equal importance is working to reduce the stigma of the disease and encourage early diagnosis, as it is in the earliest stages of disease where new medicines are likely to have greatest impact.
“We’re working on both therapeutic and diagnostic approaches to help improve the overall patient experience. Our BIA membership will support us to do this and allow us to showcase the abundance of potential and innovation within Aberdeen’s life sciences sector.”
Rebecca will discuss the opportunities for life sciences companies in North east Scotland at a BIA panel session on 10 May. Register for BIA Regional Focus: Aberdeen, taking place at ONE BioHub, here.
